Lilly’s $2.4B Bet on Cochlear Gene Therapy (2026)
Eli Lilly spent $2.4 billion on cochlear gene therapy in six months in 2025-2026. That’s not a side project.
- $1.12 billion — Seamless Therapeutics (programmable recombinases, cochlear focus), January 2026
- $1.3 billion — Rznomics (RNA editing), May 2025
The Seamless deal is specifically relevant to STRC. Seamless is developing programmable serine recombinases for hearing loss gene delivery. The technology inserts full-length DNA at a specific genomic location without double-strand breaks and without AAV size constraints.
Why this matters for STRC
Full STRC cDNA is 5,325 bp — too large for AAV. The three current workarounds are dual-AAV (co-transduction bottleneck), mini-STRC truncation (loses N-terminal function), and prime editing (maternal allele only). Recombinases solve all three problems at once: full-length sequence, single vector, permanent integration.
The comparison:
| Property | Dual-AAV | Mini-STRC | Recombinase |
|---|---|---|---|
| Payload | Full (split 2×) | Truncated (3.2-3.5 kb) | Full (single insertion) |
| Vectors | 2 AAV | 1 AAV | 1 (AAV or LNP) |
| Integration | Episomal | Episomal | Genomic (permanent) |
| Human co-transduction | 27.3% | 77.8% | Unknown |
| Cochlear data | Mouse | Computational | None yet |
The honest limitation
Nobody has demonstrated recombinase-mediated gene insertion in cochlear OHCs. The Lilly deal covers the platform, not a specific STRC program. Integration efficiency in post-mitotic cells, off-target insertion rates, and OHC-specific delivery are all open. Realistic timeline for STRC-specific preclinical data: 3-5 years minimum.
Signal interpretation
Lilly is not typically wrong about large markets. DFNB16 affects roughly 1-2% of congenital hearing loss globally — estimated 2.3 million patients carry STRC mutations. If recombinases work in the inner ear, STRC is an obvious early target: the gene is known, the disease is well-characterized, OHCs survive (no need to regenerate cells), and the gene size problem is exactly what recombinases solve.
The mini-STRC approach remains valid on a shorter timeline. But recombinases are the direct solution rather than the workaround.
Connections
[part-of]STRC Programmable Recombinases — extends the hypothesis note with industry data[see-also]STRC Mini-STRC Single-Vector Hypothesis — the nearer-term alternative[see-also]STRC Dual-Vector vs Single-Vector Transduction — the co-transduction problem recombinases bypass[see-also]STRC Anti-AAV Immune Response Model — episomal loss problem that integration solves[about]Misha